Journal: American Journal of Physiology - Endocrinology and Metabolism

Article Title: Defining the contribution of skeletal muscle pyruvate dehydrogenase α1 to exercise performance and insulin action

doi: 10.1152/ajpendo.00241.2018

Figure Lengend Snippet: Quantitative PCR primer sequences

Article Snippet: The following antibodies were used: PDHα (cat. no. 3205, Cell Signaling), eukaryotic translation elongation factor 2 (cat. no. 2332, Cell signaling), ATP synthase subunit alpha, ubiquinol-cytochrome C reductase core protein 2, mitochondrially encoded cytochrome C oxidase I, succinate dehydrogenase subunit B, NADH/ubiquinone oxidoreductase subunit B8 (cat. no. MS-604, MitoSciences), acyl-Coenzyme A dehydrogenase, very long-chain; cat. no. ab-155138, Abcam), acyl-Coenzyme A dehydrogenase, long-chain (cat. no. ab-82853, Abcam), hexokinase 2 (HK2; cat. no. 2857, Cell Signaling), lactate dehydrogenase A (cat. no. ABN-896, MilliporeSigma), Akt (cat. no. 2920, Cell Signaling), pAkt S473 (cat. no. 4058, Cell Signaling), GSK3α/β (5676, Cell signaling), pGSK3α/β S21/S9 (9331, Cell signaling), PDK4 (cat. no. NBP1-07047SS, Novus Biologicals), phosphofructokinase 1 (cat. no. sc-377346, Santa Cruz Biotechnology).

Techniques: Real-time Polymerase Chain Reaction

Journal: American Journal of Physiology - Endocrinology and Metabolism

Article Title: Defining the contribution of skeletal muscle pyruvate dehydrogenase α1 to exercise performance and insulin action

doi: 10.1152/ajpendo.00241.2018

Figure Lengend Snippet: Metabolic and mitochondrial proteins in HFD-fed PDHmKO and WT mice. WT and PDHmKO mice were fed either a chow or a HFD for 12 wk. Transcript abundance of Pdha1, Pdk2, and Pdk4 (A) and Cd36, Cact (Slc25a20), and Acadl (B) in skeletal muscle from chow- or HFD-fed PDHmKO and WT mice, normalized to Ppib (Chow, n = 5/6; HFD, n = 6/7). Representative blot of PDHα, HK2, LDHA, ACADVL (C), and ATP5A, UQCRC2, MTCO1, SDHB, and NDUFB8 (D) protein abundance in skeletal muscle from chow- or HFD-fed PDHmKO and WT mice. Bar graphs show quantification of protein abundance in skeletal muscle relative to ponceau (Chow, n = 6/6; HFD, n = 6/6) (E). Data reported as means ± SE two-way ANOVA, #P < 0.05, main effect of diet, *P < 0.05, main effect of genotype (A–E). HFD, high-fat diet; PDHmKO, tamoxifen-inducible Pdha1 knockout mice; WT, wild-type.

Article Snippet: The following antibodies were used: PDHα (cat. no. 3205, Cell Signaling), eukaryotic translation elongation factor 2 (cat. no. 2332, Cell signaling), ATP synthase subunit alpha, ubiquinol-cytochrome C reductase core protein 2, mitochondrially encoded cytochrome C oxidase I, succinate dehydrogenase subunit B, NADH/ubiquinone oxidoreductase subunit B8 (cat. no. MS-604, MitoSciences), acyl-Coenzyme A dehydrogenase, very long-chain; cat. no. ab-155138, Abcam), acyl-Coenzyme A dehydrogenase, long-chain (cat. no. ab-82853, Abcam), hexokinase 2 (HK2; cat. no. 2857, Cell Signaling), lactate dehydrogenase A (cat. no. ABN-896, MilliporeSigma), Akt (cat. no. 2920, Cell Signaling), pAkt S473 (cat. no. 4058, Cell Signaling), GSK3α/β (5676, Cell signaling), pGSK3α/β S21/S9 (9331, Cell signaling), PDK4 (cat. no. NBP1-07047SS, Novus Biologicals), phosphofructokinase 1 (cat. no. sc-377346, Santa Cruz Biotechnology).

Techniques: Quantitative Proteomics, Knock-Out

Journal: American Journal of Physiology - Endocrinology and Metabolism

Article Title: Defining the contribution of skeletal muscle pyruvate dehydrogenase α1 to exercise performance and insulin action

doi: 10.1152/ajpendo.00241.2018

Figure Lengend Snippet: PDHmKO mice have reduced running speed during voluntary wheel running (VWR). Weekly average speed (km/h) (A), distance run per 24-h period (B), and time/24 h spent running (C) over 21 days VWR (n = 7/6). Representative blots of PDHα, HK2, PFK1, LDH, PDK4, ACADVL, ACADL, and NDUFB8 protein abundance in skeletal muscle from sedentary (SED) or exercise-trained (EXT) PDHmKO and WT mice (D). Bar graphs show quantification of protein abundance in skeletal muscle relative to ponceau (SED, n = 5/5; EXT, n = 7/6) (E). Data reported as means ± SE 2-way ANOVA, Sidak’s post hoc test, *P < 0.05, PDHmKO compared with WT (A–C); 2-way ANOVA, Tukey’s post hoc test, #P < 0.05, EXT compared with SED, *P < 0.05, PDHmKO compared with WT (D–E). PDHmKO, tamoxifen-inducible Pdha1 knockout mice; WT, wild-type.

Article Snippet: The following antibodies were used: PDHα (cat. no. 3205, Cell Signaling), eukaryotic translation elongation factor 2 (cat. no. 2332, Cell signaling), ATP synthase subunit alpha, ubiquinol-cytochrome C reductase core protein 2, mitochondrially encoded cytochrome C oxidase I, succinate dehydrogenase subunit B, NADH/ubiquinone oxidoreductase subunit B8 (cat. no. MS-604, MitoSciences), acyl-Coenzyme A dehydrogenase, very long-chain; cat. no. ab-155138, Abcam), acyl-Coenzyme A dehydrogenase, long-chain (cat. no. ab-82853, Abcam), hexokinase 2 (HK2; cat. no. 2857, Cell Signaling), lactate dehydrogenase A (cat. no. ABN-896, MilliporeSigma), Akt (cat. no. 2920, Cell Signaling), pAkt S473 (cat. no. 4058, Cell Signaling), GSK3α/β (5676, Cell signaling), pGSK3α/β S21/S9 (9331, Cell signaling), PDK4 (cat. no. NBP1-07047SS, Novus Biologicals), phosphofructokinase 1 (cat. no. sc-377346, Santa Cruz Biotechnology).

Techniques: Quantitative Proteomics, Knock-Out

Journal: Oncotarget

Article Title: Mitochondrial targeted HSP90 inhibitor Gamitrinib-TPP (G-TPP) induces PINK1/Parkin-dependent mitophagy

doi: 10.18632/oncotarget.22287

Figure Lengend Snippet: ( A ) G-TPP treatment leads to PINK1 stabilization and pS65-Ub induction in HeLa cells. HeLa cells stably expressing untagged Parkin were treated with 10 µM G-TPP for the indicated times. Western blots were prepared with cell lysates and probed with antibodies against PINK1 and pS65-Ub. GAPDH served as a loading control. ( B ) pS65-Ub is induced in G-TPP treated cells and co-localizes with EGFP-Parkin and mitochondria. HeLa cells stably expressing EGFP-Parkin (green) were treated with 10 µM G-TPP for the indicated times and fixed. Cells were stained with antibodies against pS65-Ub (red) and the mitochondrial marker TOM20 (cyan). Scale bars correspond to 10 µM. ( C ) Quantification of Parkin translocation using High Content Imaging. HeLa EGFP-Parkin cells were treated for 4 or 8 h with or without 10 µM G-TPP. CCCP treatment (10 µM for 2 h) was used as a positive control. Cells were fixed, counterstained with Hoechst dye to visualize nuclei, imaged and analyzed using the ratio of cytoplasmic to nuclear EGFP signal . Data was normalized to positive (2 h 10 µM CCCP treatment) and negative (2 h DMSO) controls. G-TPP significantly induced Parkin re-localization to levels similar to or beyond 2 h CCCP treatment. Shown are the mean values of three independent experiments with triplicate wells each ± SEM (one-way ANOVA with Tukey’s posthoc, *** p < 0.0005).

Article Snippet: The following antibodies have been used for western blot (WB) or immunofluorescence (IF): beta III tubulin (#5568, CST, WB: 1/2,000 or AB9354, Millipore, IF: 1/250), FLAG (F3165, Sigma, WB: 1/150,000), GAPDH (H86504M, Meridian Life Sciences, WB: 1/500,000), LC3B (NB100-2220, Novus Biologicals, WB: 1/5,000), Miro1 (H00055288-M01, Novus Biologicals, WB: 1/500), Mitofusin 1 (ab57602, Abcam, WB: 1/5,000), Mitofusin 2 (ab56889, Abcam, WB: 1/5,000), NBR1 (H00004077-M01, Abnova, WB: 1/500, IF: 1/100), NDP52 (12229-1-AP, PTG, WB: 1/1,000, IF: 1/400), OPTN (sc-166576, Santa Cruz, IF: 1/100), OPTN (10837-1-AP, PTG, WB: 1/5,000), p38 (#9212, CST, WB: 1/2,000), p62 (610832, BD Biosciences, WB: 1/2,000, IF:1/500), Parkin (#4211, CST, WB: 1/3,000), PGAM5 (ab12653, Abcam, WB: 1/5,000), PINK1 (#6946, CST, WB: 1/2,000, IF: 1/1,000), PINK1 (BC100-494, Novus Biologicals, WB: 1/2,000), TAX1BP1 (#5105, CST, WB: 1/2,000, IF: 1/400), TBK1 (#3504, CST, WB: 1/1,000), pS172-TBK1 (#5483, CST, WB: 1/1,000), TOM20 rabbit (11802-1-AP, PTG, IF: 1/2,000), TOM20 mouse (sc-17764, Santa Cruz, IF: 1/100), TOM70 (14528-1-AP, PTG, WB: 1/5,000), TRAP1 (#13405, CST, WB: 1/1,000), ubiquitin (#3933, CST, WB: 1/2,000), pS65-Ub (in-house [ , ], WB: 1/15,000, IF: 1/250), VDAC1 (ab14734, Abcam, WB: 1/10,000), vinculin (V9131, Sigma, WB: 1/500,000).

Techniques: Stable Transfection, Expressing, Western Blot, Control, Staining, Marker, Translocation Assay, Imaging, Positive Control

Journal: Oncotarget

Article Title: Mitochondrial targeted HSP90 inhibitor Gamitrinib-TPP (G-TPP) induces PINK1/Parkin-dependent mitophagy

doi: 10.18632/oncotarget.22287

Figure Lengend Snippet: ( A , B ) HeLa cells stably expressing EGFP-Parkin were treated with 12 different concentrations of G-TPP or 17-AAG in a dose-response format for 2 or 6 h before adding (A) DMSO or (B) CCCP (final assay concentration = 10 µM) for an additional 2 h. Cells were fixed and analyzed for Parkin translocation (black line). Cell number was assessed by counting the number of Hoechst-positive nuclei in each well (gray line). Values were normalized to positive (2 h 10 µM CCCP) and negative (2 h DMSO) controls. In absence of CCCP, only G-TPP but not 17-AAG induced Parkin translocation. In combination with CCCP, increasing doses of 17-AAG led to inhibition of Parkin translocation. Very high concentrations of G-TPP also inhibited Parkin translocation and resulted in cell toxicity. ( C ) HeLa cells expressing untagged Parkin were treated with 1 µM 17-AAG, 10 µM G-TPP or DMSO as a control for 6 h before CCCP (10 µM) or medium containing DMSO was added for 4 h. Cells were harvested and western blots probed with antibodies against PINK1, pS65-Ub, the mitochondrial phosphatase PGAM5. Vinculin was used as a loading control. Compared to controls, 17-AAG pre-treated cells showed lower PINK1 levels that were accompanied by reduced pS65-Ub induction upon CCCP treatment, while G-TPP pre-treatment led to induction of pS65-Ub in the absence of CCCP, as expected.

Article Snippet: The following antibodies have been used for western blot (WB) or immunofluorescence (IF): beta III tubulin (#5568, CST, WB: 1/2,000 or AB9354, Millipore, IF: 1/250), FLAG (F3165, Sigma, WB: 1/150,000), GAPDH (H86504M, Meridian Life Sciences, WB: 1/500,000), LC3B (NB100-2220, Novus Biologicals, WB: 1/5,000), Miro1 (H00055288-M01, Novus Biologicals, WB: 1/500), Mitofusin 1 (ab57602, Abcam, WB: 1/5,000), Mitofusin 2 (ab56889, Abcam, WB: 1/5,000), NBR1 (H00004077-M01, Abnova, WB: 1/500, IF: 1/100), NDP52 (12229-1-AP, PTG, WB: 1/1,000, IF: 1/400), OPTN (sc-166576, Santa Cruz, IF: 1/100), OPTN (10837-1-AP, PTG, WB: 1/5,000), p38 (#9212, CST, WB: 1/2,000), p62 (610832, BD Biosciences, WB: 1/2,000, IF:1/500), Parkin (#4211, CST, WB: 1/3,000), PGAM5 (ab12653, Abcam, WB: 1/5,000), PINK1 (#6946, CST, WB: 1/2,000, IF: 1/1,000), PINK1 (BC100-494, Novus Biologicals, WB: 1/2,000), TAX1BP1 (#5105, CST, WB: 1/2,000, IF: 1/400), TBK1 (#3504, CST, WB: 1/1,000), pS172-TBK1 (#5483, CST, WB: 1/1,000), TOM20 rabbit (11802-1-AP, PTG, IF: 1/2,000), TOM20 mouse (sc-17764, Santa Cruz, IF: 1/100), TOM70 (14528-1-AP, PTG, WB: 1/5,000), TRAP1 (#13405, CST, WB: 1/1,000), ubiquitin (#3933, CST, WB: 1/2,000), pS65-Ub (in-house [ , ], WB: 1/15,000, IF: 1/250), VDAC1 (ab14734, Abcam, WB: 1/10,000), vinculin (V9131, Sigma, WB: 1/500,000).

Techniques: Stable Transfection, Expressing, Concentration Assay, Translocation Assay, Inhibition, Control, Western Blot

Journal: Oncotarget

Article Title: Mitochondrial targeted HSP90 inhibitor Gamitrinib-TPP (G-TPP) induces PINK1/Parkin-dependent mitophagy

doi: 10.18632/oncotarget.22287

Figure Lengend Snippet: ( A , C ) Fibroblasts were treated with 15 µM G-TPP for the indicated time points. Cells were harvested and western blots were probed with antibodies against (A) PINK1, pS65-Ub and total Ub or (C) autophagy adapter proteins. GAPDH and Vinculin served as loading control. G-TPP treatment led to PINK1 stabilization and pS65-Ub induction in primary skin fibroblasts. p62 levels were induced upon G-TPP treatment, while other adapters seemed decreased. ( B , D ) Human fibroblasts were treated with 15 µM G-TPP for 16 h and fixed and stained with antibodies against (B) pS65-Ub (green) or (D) the autophagy adapters NBR1, NDP52, p62, OPTN and TAX1BP1 (green). Mitochondria were stained with antibodies against TOM20 (red), nuclei were visualized with Hoechst (blue). Scale bars indicate 10 µM. A magnified image of the boxed region, the fluorescence profile along the arrow and the Pearson’s correlation coefficient of adapter protein and mitochondrial stainingare shown to the right. Shown is the mean ± SEM of at least five randomly selected images (unpaired, two-sided t -test, *** p < 0.0005).

Article Snippet: The following antibodies have been used for western blot (WB) or immunofluorescence (IF): beta III tubulin (#5568, CST, WB: 1/2,000 or AB9354, Millipore, IF: 1/250), FLAG (F3165, Sigma, WB: 1/150,000), GAPDH (H86504M, Meridian Life Sciences, WB: 1/500,000), LC3B (NB100-2220, Novus Biologicals, WB: 1/5,000), Miro1 (H00055288-M01, Novus Biologicals, WB: 1/500), Mitofusin 1 (ab57602, Abcam, WB: 1/5,000), Mitofusin 2 (ab56889, Abcam, WB: 1/5,000), NBR1 (H00004077-M01, Abnova, WB: 1/500, IF: 1/100), NDP52 (12229-1-AP, PTG, WB: 1/1,000, IF: 1/400), OPTN (sc-166576, Santa Cruz, IF: 1/100), OPTN (10837-1-AP, PTG, WB: 1/5,000), p38 (#9212, CST, WB: 1/2,000), p62 (610832, BD Biosciences, WB: 1/2,000, IF:1/500), Parkin (#4211, CST, WB: 1/3,000), PGAM5 (ab12653, Abcam, WB: 1/5,000), PINK1 (#6946, CST, WB: 1/2,000, IF: 1/1,000), PINK1 (BC100-494, Novus Biologicals, WB: 1/2,000), TAX1BP1 (#5105, CST, WB: 1/2,000, IF: 1/400), TBK1 (#3504, CST, WB: 1/1,000), pS172-TBK1 (#5483, CST, WB: 1/1,000), TOM20 rabbit (11802-1-AP, PTG, IF: 1/2,000), TOM20 mouse (sc-17764, Santa Cruz, IF: 1/100), TOM70 (14528-1-AP, PTG, WB: 1/5,000), TRAP1 (#13405, CST, WB: 1/1,000), ubiquitin (#3933, CST, WB: 1/2,000), pS65-Ub (in-house [ , ], WB: 1/15,000, IF: 1/250), VDAC1 (ab14734, Abcam, WB: 1/10,000), vinculin (V9131, Sigma, WB: 1/500,000).

Techniques: Western Blot, Control, Staining, Fluorescence

Journal: Oncotarget

Article Title: Mitochondrial targeted HSP90 inhibitor Gamitrinib-TPP (G-TPP) induces PINK1/Parkin-dependent mitophagy

doi: 10.18632/oncotarget.22287

Figure Lengend Snippet: ( A ) Control cells or PINK1 Q456X fibroblasts were converted to induced neurons (iNeurons). Cells were treated for the indicated times with 10 µM G-TPP and harvested. Western blots were prepared and probed with antibodies against PINK1, pS65-Ub and Parkin. Beta III tubulin served as a control for successful conversion to neuronal cells, GAPDH as a loading control. ( B ) iNeurons were treated with 15 µM G-TPP for 8 h and fixed. Cells were stained with antibodies against pS65-Ub (green) and the mitochondrial marker TOM20 (red) and the neuronal marker Beta III tubulin (cyan). Nuclei were stained with Hoechst 33342 (blue). Scale bars correspond to 10 µM. A magnified image of the boxed region and the fluorescence profile along the arrow are shown to the right.

Article Snippet: The following antibodies have been used for western blot (WB) or immunofluorescence (IF): beta III tubulin (#5568, CST, WB: 1/2,000 or AB9354, Millipore, IF: 1/250), FLAG (F3165, Sigma, WB: 1/150,000), GAPDH (H86504M, Meridian Life Sciences, WB: 1/500,000), LC3B (NB100-2220, Novus Biologicals, WB: 1/5,000), Miro1 (H00055288-M01, Novus Biologicals, WB: 1/500), Mitofusin 1 (ab57602, Abcam, WB: 1/5,000), Mitofusin 2 (ab56889, Abcam, WB: 1/5,000), NBR1 (H00004077-M01, Abnova, WB: 1/500, IF: 1/100), NDP52 (12229-1-AP, PTG, WB: 1/1,000, IF: 1/400), OPTN (sc-166576, Santa Cruz, IF: 1/100), OPTN (10837-1-AP, PTG, WB: 1/5,000), p38 (#9212, CST, WB: 1/2,000), p62 (610832, BD Biosciences, WB: 1/2,000, IF:1/500), Parkin (#4211, CST, WB: 1/3,000), PGAM5 (ab12653, Abcam, WB: 1/5,000), PINK1 (#6946, CST, WB: 1/2,000, IF: 1/1,000), PINK1 (BC100-494, Novus Biologicals, WB: 1/2,000), TAX1BP1 (#5105, CST, WB: 1/2,000, IF: 1/400), TBK1 (#3504, CST, WB: 1/1,000), pS172-TBK1 (#5483, CST, WB: 1/1,000), TOM20 rabbit (11802-1-AP, PTG, IF: 1/2,000), TOM20 mouse (sc-17764, Santa Cruz, IF: 1/100), TOM70 (14528-1-AP, PTG, WB: 1/5,000), TRAP1 (#13405, CST, WB: 1/1,000), ubiquitin (#3933, CST, WB: 1/2,000), pS65-Ub (in-house [ , ], WB: 1/15,000, IF: 1/250), VDAC1 (ab14734, Abcam, WB: 1/10,000), vinculin (V9131, Sigma, WB: 1/500,000).

Techniques: Control, Western Blot, Staining, Marker, Fluorescence

Journal: Cell reports

Article Title: 2-Hydroxyglutarate destabilizes chromatin regulatory landscape and lineage fidelity to promote cellular heterogeneity

doi: 10.1016/j.celrep.2021.110220

Figure Lengend Snippet:

Article Snippet: Primary antibodies used were as follows: PNCA (Cell Signaling Technologies, 13110), BRCA1 (Cell Signaling Technologies, 9010), RAD51C (Novus Biologicals, NB100–177), BRIP1 (Novus Biologicals, NBP1–31883), MSH2 (Novus Biologicals, NBP3–07211), FANCD2 (Novus Biologicals, NB100–182), FEN1 (Novus Biologicals, NB100–150), XRCC2 (Abcam, ab180752), and β-actin (R&D Systems, MAB8929).

Techniques: Recombinant, Control, Blocking Assay, Suspension, Electron Microscopy, Purification, Whole Genome Amplification, SYBR Green Assay, Labeling, Staining, Methylation Sequencing, Methylated DNA Immunoprecipitation, Biomarker Discovery, Software, Pyromark Assay

Journal: Journal of Translational Medicine

Article Title: Are morphological criteria sufficient for the identification of circulating tumor cells in renal cancer?

doi: 10.1186/1479-5876-11-214

Figure Lengend Snippet: Summary of the immunocytochemical analysis of CNHCs with antibodies against CD45, CD31, and CAIX

Article Snippet: The filters were incubated with primary antibodies directed against CAIX (rabbit IgG, NB100-417, Novus Biologicals, Littleton, USA; 3.5 μg/ml ), CD31 (mouse IgG1, M0823, Dako, Glostrup, Denmark; 1 μg/ml) or CD45 (mouse IgG1, M0855, Dako, Glostrup, Denmark; 2.4 μg/ml) diluted in Antibody Diluent (Dako, Glostrup, Denmark) for 30 min at RT followed by application of primary antibody enhancer (Dako, Glostrup, Denmark) for 15 min.

Techniques:

Journal: Journal of Translational Medicine

Article Title: Are morphological criteria sufficient for the identification of circulating tumor cells in renal cancer?

doi: 10.1186/1479-5876-11-214

Figure Lengend Snippet: Immunocytochemical analysis of CNHCs with antibodies against the RCC marker CAIX. Clusters of CNHCs cytomorphologically classified as uncertain malignant (−UMF) with cytoplasmic positive staining with antibodies against the RCC marker CAIX (A) . Clusters of CNHC-UMF and -BF without reactivity for CAIX antibodies ( B and C , respectively). A single CNHC-MF with positive cytoplasmic (D) and without staining for CAIX (E) . Single CAIX-negative CNHC-UMF and -BF ( F and G , respectively).

Article Snippet: The filters were incubated with primary antibodies directed against CAIX (rabbit IgG, NB100-417, Novus Biologicals, Littleton, USA; 3.5 μg/ml ), CD31 (mouse IgG1, M0823, Dako, Glostrup, Denmark; 1 μg/ml) or CD45 (mouse IgG1, M0855, Dako, Glostrup, Denmark; 2.4 μg/ml) diluted in Antibody Diluent (Dako, Glostrup, Denmark) for 30 min at RT followed by application of primary antibody enhancer (Dako, Glostrup, Denmark) for 15 min.

Techniques: Marker, Staining

Journal: Frontiers in Pharmacology

Article Title: Changes in PGC‐1α/SIRT1 Signaling Impact on Mitochondrial Homeostasis in Amyloid-Beta Peptide Toxicity Model

doi: 10.3389/fphar.2020.00709

Figure Lengend Snippet: Acute effects of AβOs on total levels of proteins that regulate mitochondrial dynamics. (A) Mfn1 and (B) DRP1 western blot of lysates from PC12 cells treated with FCCP (10 μM, 2 h) and AβOs (0.5 μM, 1 and 2 h). A dotted line on the western blot indicates different regions of the same gel. (C, D) Quantification of Mfn1 and DRP1 levels normalized to beta actin. Data are represented as mean ± SEM. *p < 0.05, **p < 0.01 compared between the control group. One-way ANOVA with the Dunnett's multiple comparisons test was used for all statistical analyses. Mfn1, mitofusin 1; DRP1, dynamin-related protein 1. (n = 4–5 for each group) (original gel blot are provided on ).

Article Snippet: Samples were incubated for 1 h at RT with the following primary antibodies: SIRT1 (mouse 1:300, Novus Biologicals, IF3), PGC-1α (rabbit 1:400, Novus Biologicals, NBP1-04676), Ser-46 SIRT1 (Sigma 1:200, SAB4301426), DRP1 (rabbit 1:200, Novus Biologicals, NB 110-55288), and Mfn1 (rabbit 1:200, Novus Biologicals, NBP1-51841).

Techniques: Western Blot, Control

Journal: Frontiers in Pharmacology

Article Title: Changes in PGC‐1α/SIRT1 Signaling Impact on Mitochondrial Homeostasis in Amyloid-Beta Peptide Toxicity Model

doi: 10.3389/fphar.2020.00709

Figure Lengend Snippet: Acute effects of AβOs on immunoreactivity of proteins that regulate mitochondrial dynamics. Representative epifluorescence images of (A) Mfn1 and (B) DRP1 immunoreactivity in PC-12 cells control and treated with AβOs (0.5 μM) for 1 and 2 h. Quantification of (C) Mfn1 and (D) DRP1 immunoreactivity (intensity), under the same experimental conditions. Scale bars: 20 μm. Data are represented as mean ± SEM. *p < 0.05, ***p < 0.001 compared between the control group. One-way ANOVA with the Dunn's multiple comparisons test was used for all statistical analyses. Mfn1, mitofusin 1; DRP1, dynamin-related protein 1. (n=3–6 for each group, N= 56–103) (entire inmunocytochemistry for Mfn1 and DRP1 with control are provided on ).

Article Snippet: Samples were incubated for 1 h at RT with the following primary antibodies: SIRT1 (mouse 1:300, Novus Biologicals, IF3), PGC-1α (rabbit 1:400, Novus Biologicals, NBP1-04676), Ser-46 SIRT1 (Sigma 1:200, SAB4301426), DRP1 (rabbit 1:200, Novus Biologicals, NB 110-55288), and Mfn1 (rabbit 1:200, Novus Biologicals, NBP1-51841).

Techniques: Control

Journal: Frontiers in Pharmacology

Article Title: Changes in PGC‐1α/SIRT1 Signaling Impact on Mitochondrial Homeostasis in Amyloid-Beta Peptide Toxicity Model

doi: 10.3389/fphar.2020.00709

Figure Lengend Snippet: Model of alterations induced on SIRT1/PGC-1α pathway by AβOs. (A) . Healthy neuronal conditions were energy depletion and/or decreased catabolic rates can be sensed by SIRT1 promoting the PGC-1α deacetylation (1). Transcription and co-activates of factors like NRF- 1/2 for the expression of nuclear-encoded mitochondrial genes and dynamic mitochondrial proteins, requires of PGC-1α translocation (2). Coordinated mitochondrial dynamics (3, fission/fusion), depends of adequate expression of Mfn1, Drp1. (B) . In AβOs treated neurons, the PGC-1α is unable to be deacetylated and to translocate to the nucleus (4). The expression of key genes is loss (5), and imbalance between fusion and fission to promote the granular mitochondrial phenotype (6) and neuronal death.

Article Snippet: Samples were incubated for 1 h at RT with the following primary antibodies: SIRT1 (mouse 1:300, Novus Biologicals, IF3), PGC-1α (rabbit 1:400, Novus Biologicals, NBP1-04676), Ser-46 SIRT1 (Sigma 1:200, SAB4301426), DRP1 (rabbit 1:200, Novus Biologicals, NB 110-55288), and Mfn1 (rabbit 1:200, Novus Biologicals, NBP1-51841).

Techniques: Expressing, Translocation Assay

Journal: Nucleic Acids Research

Article Title: p53 coordinates base excision repair to prevent genomic instability

doi: 10.1093/nar/gkw015

Figure Lengend Snippet: Persistent SSBs decrease APE1 levels by affecting its transcription. ( A ) Western blotting analysis on a representative XRCC1 knockdown time-course. TIG-1 cells were incubated with either a control siRNA (72 h), or a XRCC1-targeting siRNA, and harvested at the indicated time points. DNA damage accumulation is highlighted by PAR formation; APE1 is downregulated in a time-dependent manner. Actin was used as loading control. ( B ) Alkaline Comet assay on TIG-1 cells harvested 72 h after XRCC1 depletion shows accumulation of SSBs ( N = 9). ( C ) Histogram showing the downregulation in APE1 protein amount 72 h after XRCC1 knockdown, as measured by western blotting ( N = 10). ( D ) Histogram showing the downregulation in APE1 transcript level 72 h after XRCC1 depletion, as measured by qPCR ( N = 7). Results depicted in histograms are presented as mean ± SD of the indicated number ( N ) of independent experiments.

Article Snippet: Membranes were probed with the following antibodies: APE1 (Novus Biologicals, NB100–101), XRCC1 (Thermo Scientific, MS-1393-P0), α-actin (Abcam, ab6276), p21 (Cell Signaling Technology, 2947), p53 (Santa Cruz, sc-126), PAR (Trevigen, 4335-AMC-050), histone H2A.X phosphorylated at Ser139 (γH2AX, 05–636, Millipore), Sp1 (Millipore, 07–645), histone H3 (Cell Signaling Technology, 4499).

Techniques: Western Blot, Knockdown, Incubation, Control, Alkaline Single Cell Gel Electrophoresis

Journal: Nucleic Acids Research

Article Title: p53 coordinates base excision repair to prevent genomic instability

doi: 10.1093/nar/gkw015

Figure Lengend Snippet: Downregulation of APE1 in response to BER unbalance is dependent of p53. ( A ) Representative western blotting analysis on TIG-1 cells depleted of XRCC1 and p53. APE1 is downregulated upon XRCC1 knockdown in a p53-dependent manner. Actin was used as loading control. ( B ) Left: histogram showing the quantification of APE1 protein amount in the experiment showed in panel A ( N = 5). Right: histogram illustrating the amount of APE1 transcript upon combined XRCC1/p53 depletion, as measured through qPCR ( N = 3). Results are expressed as mean ± SD of the indicated number ( N ) of independent experiments. ( C ) Boxplot showing the distribution of APE1 staining intensity (in arbitrary units) in p53 low versus p53 overexpressing cells. The dashed line highlights the median APE1 intensity in p53 low cells ( N > 8000). ( D ) Representative high-throughput immuno-fluorescence pictures showing TIG-1 cells stained for APE1 (right panel) and p53 (middle panel) after transfection with a p53 expressing plasmid. Cells that downregulating APE1 in response to p53 overexpression are marked by a contour line.

Article Snippet: Membranes were probed with the following antibodies: APE1 (Novus Biologicals, NB100–101), XRCC1 (Thermo Scientific, MS-1393-P0), α-actin (Abcam, ab6276), p21 (Cell Signaling Technology, 2947), p53 (Santa Cruz, sc-126), PAR (Trevigen, 4335-AMC-050), histone H2A.X phosphorylated at Ser139 (γH2AX, 05–636, Millipore), Sp1 (Millipore, 07–645), histone H3 (Cell Signaling Technology, 4499).

Techniques: Western Blot, Knockdown, Control, Staining, High Throughput Screening Assay, Fluorescence, Transfection, Expressing, Plasmid Preparation, Over Expression

Journal: Nucleic Acids Research

Article Title: p53 coordinates base excision repair to prevent genomic instability

doi: 10.1093/nar/gkw015

Figure Lengend Snippet: Defective p53 activity leads to failure of the BER coordination system. ( A ) High-throughput microscopy analysis of TIG-1 cells transfected with plasmids expressing wild-type or mutant p53. Boxplots showing the distribution of APE1 staining intensity (in arbitrary units) in p53 low versus p53 overexpressing cells. Each p53 mutant is reported on top of the relevant plot. The dashed line highlights the median APE1 intensity in p53 low cells ( N > 5000). NS: not statistically significant at P < 0.05. ( B ) Representative western blotting analysis comparing WI38 and WI38 (SV40) cells upon transfection with the indicated siRNAs. Failure to downregulate Sp1 correlates with the inability to modulate APE1. Actin was used as loading control. ( C ) qPCR analysis on APE1 transcript in WI38 and WI38 (SV40) cells upon transfection with the indicated siRNAs. APE1 transcription is reduced in WI38 cells only. Note the higher transcript content in WI38 (SV40) cells. ( D ) Representative Western blotting analysis comparing WI38 and WI38 (SV40) cells upon transfection with the indicated siRNAs. Failure to modulate BER correlates with γH2AX staining in WI38 (SV40) cells; γH2AX increases further upon XRCC1 depletion. ( E ) Neutral Comet assay on WI38 and WI38 (SV40) fibroblasts shows accumulation of DSBs upon XRCC1-depletion in transformed cells only. Results are expressed as mean ± SD of three independent experiments.

Article Snippet: Membranes were probed with the following antibodies: APE1 (Novus Biologicals, NB100–101), XRCC1 (Thermo Scientific, MS-1393-P0), α-actin (Abcam, ab6276), p21 (Cell Signaling Technology, 2947), p53 (Santa Cruz, sc-126), PAR (Trevigen, 4335-AMC-050), histone H2A.X phosphorylated at Ser139 (γH2AX, 05–636, Millipore), Sp1 (Millipore, 07–645), histone H3 (Cell Signaling Technology, 4499).

Techniques: Activity Assay, High Throughput Screening Assay, Microscopy, Transfection, Expressing, Mutagenesis, Staining, Western Blot, Control, Neutral Comet Assay, Transformation Assay

Journal: Nucleic Acids Research

Article Title: p53 coordinates base excision repair to prevent genomic instability

doi: 10.1093/nar/gkw015

Figure Lengend Snippet: Excessive AP-endonuclease activity in cells with p53 impairment leads to accumulation of genomic instability. ( A ) Representative western blotting analysis on WI38 (SV40) cells shows rescue of γH2AX staining upon co-depletion of XRCC1 and APE1. ( B ) Neutral Comet assay on WI38 (SV40) fibroblasts shows accumulation of DSBs upon XRCC1-depletion and rescue after co-depletion of XRCC1 and APE1. Results are expressed as mean ± SD of three independent experiments. ( C ) Representative western blotting analysis on WI38 (SV40) cells shows rescue of γH2AX staining after depletion of XRCC1 in presence of APE1 inhibitor III (APE1i III, 5 μM for 24 h), or AR03 (2.5 μM for 24 h). Actin was used as loading control in all western blotting experiments.

Article Snippet: Membranes were probed with the following antibodies: APE1 (Novus Biologicals, NB100–101), XRCC1 (Thermo Scientific, MS-1393-P0), α-actin (Abcam, ab6276), p21 (Cell Signaling Technology, 2947), p53 (Santa Cruz, sc-126), PAR (Trevigen, 4335-AMC-050), histone H2A.X phosphorylated at Ser139 (γH2AX, 05–636, Millipore), Sp1 (Millipore, 07–645), histone H3 (Cell Signaling Technology, 4499).

Techniques: Activity Assay, Western Blot, Staining, Neutral Comet Assay, Control